Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 12/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 12/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 7/20 | 0.46 |
| ▸ | ABL1 | P00519 | 2/20 | 0.40 |
| ▸ | GSK3B | P49841 | 3/20 | 0.39 |
| ▸ | WNT1 | P04628 | 2/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.39 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | GSK3A | P49840 | 1/20 | 0.38 |
| ▸ | WDR5 | P61964 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24978674 | 0.93 | HDAC1 (0.42) | HDAC1HDAC2HDAC3ABL1P2RX3 | |
| SCHEMBL23300902 | 0.91 | MAP4K1 (0.42) | ABL1KMT2A | |
| SCHEMBL23330999 | 0.88 | HDAC3 (0.40) | HDAC1HDAC2HDAC3ABL1KMT2A | |
| SCHEMBL24978407 | 0.88 | HDAC3 (0.43) | HDAC1HDAC2HDAC3KMT2A | |
| SCHEMBL23330650 | 0.86 | HDAC1 (0.47) | HDAC1HDAC2HDAC3KMT2AP2RX3 | |
| SCHEMBL23331087 | 0.84 | HDAC1 (0.47) | HDAC1HDAC2HDAC3ABL1GSK3B | |
| SCHEMBL24978425 | 0.81 | HSD17B10 (0.47) | KMT2A | |
| SCHEMBL24978418 | 0.80 | HDAC3 (0.46) | HDAC1HDAC2HDAC3KMT2A | |
| SCHEMBL23830465 | 0.80 | HDAC1 (0.47) | HDAC1HDAC2HDAC3ABL1GSK3B | |
| SCHEMBL24978673 | 0.77 | PIP5K1C (0.41) | HDAC1HDAC2HDAC3ABL1GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230028221-A1 | EED INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | JING MEDICINE TECHNOLOGY (SHANGHAI) LTD. (CN) | 2023-01-26 | — | — | US | disclosed |
| WO-2021083380-A1 | EED INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海科技大学 | 2021-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230028221-A1 | EED INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | CYP4F11, CYP4A11, HSD11B1 | HDAC1 1446/4885HDAC2 2456/4885HDAC3 3383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.